Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totaling 56,618 shares, a decrease of 78.8% from the April 15th total of 267,352 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily volume of 158,455 shares, the short-interest ratio is currently 0.4 days.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Stock Down 1.6%

Shares of NASDAQ:CYCN traded down $0.05 during trading on Wednesday, hitting $3.13. 142,964 shares of the company were exchanged, compared to its average volume of 122,523. The business’s 50 day moving average is $2.63 and its 200-day moving average is $1.89. The company has a market capitalization of $13.55 million, a P/E ratio of -2.30 and a beta of 1.80. Cyclerion Therapeutics has a 1-year low of $1.03 and a 1-year high of $8.48.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 58.21%. As a group, sell-side analysts anticipate that Cyclerion Therapeutics will post -1.2 earnings per share for the current year.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.